Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia.
Undervalued established dividend payer.
Share Price & News
How has Australian Pharmaceutical Industries's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: API has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: API underperformed the Australian Healthcare industry which returned 25.4% over the past year.
Return vs Market: API underperformed the Australian Market which returned 15.6% over the past year.
Price Volatility Vs. Market
How volatile is Australian Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Australian Pharmaceutical Industries Limited's (ASX:API) Shareholder Register?
2 months ago | Simply Wall StIs There More To Australian Pharmaceutical Industries Limited (ASX:API) Than Its 11% Returns On Capital?
2 months ago | Simply Wall StRead This Before Buying Australian Pharmaceutical Industries Limited (ASX:API) For Its Dividend
Is Australian Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: API (A$1.27) is trading below our estimate of fair value (A$1.65)
Significantly Below Fair Value: API is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: API is good value based on its PE Ratio (11.3x) compared to the Healthcare industry average (19.4x).
PE vs Market: API is good value based on its PE Ratio (11.3x) compared to the Australian market (18.8x).
Price to Earnings Growth Ratio
PEG Ratio: API's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: API is good value based on its PB Ratio (1.2x) compared to the AU Healthcare industry average (2x).
How is Australian Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: API's earnings are forecast to decline over the next 3 years (-4.4% per year).
Earnings vs Market: API's earnings are forecast to decline over the next 3 years (-4.4% per year).
High Growth Earnings: API's earnings are forecast to decline over the next 3 years.
Revenue vs Market: API's revenue (0.6% per year) is forecast to grow slower than the Australian market (4.3% per year).
High Growth Revenue: API's revenue (0.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: API's Return on Equity is forecast to be low in 3 years time (9%).
How has Australian Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: API has high quality earnings.
Growing Profit Margin: API's current net profit margins (1.4%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: API has become profitable over the past 5 years, growing earnings by 23.2% per year.
Accelerating Growth: API's earnings growth over the past year (14.7%) is below its 5-year average (23.2% per year).
Earnings vs Industry: API earnings growth over the past year (14.7%) exceeded the Healthcare industry 1.8%.
Return on Equity
High ROE: API's Return on Equity (10.8%) is considered low.
Return on Assets
Return on Capital Employed
How is Australian Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: API's short term assets (A$1.1B) exceed its short term liabilities (A$887.5M).
Long Term Liabilities: API's short term assets (A$1.1B) exceed its long term liabilities (A$255.4M).
Debt to Equity History and Analysis
Debt Level: API's debt to equity ratio (43.8%) is considered high.
Reducing Debt: API's debt to equity ratio has increased from 24.7% to 43.8% over the past 5 years.
Debt Coverage: API's debt is not well covered by operating cash flow (5.1%).
Interest Coverage: API's interest payments on its debt are well covered by EBIT (14x coverage).
Inventory Level: API has a high level of physical assets or inventory.
Debt Coverage by Assets: API's debt is covered by short term assets (assets are 4.8x debt).
What is Australian Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: API's dividend (6.13%) is higher than the bottom 25% of dividend payers in the Australian market (2.31%).
High Dividend: API's dividend (6.13%) is in the top 25% of dividend payers in the Australian market (5.48%)
Stability and Growth of Payments
Stable Dividend: API's dividend payments have been volatile in the past 10 years.
Growing Dividend: API's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (69.3%), API's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: API's dividends in 3 years are forecast to be covered by earnings (76.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richard Vincent 0
Mr. Richard C. Vincent, B.Bus, (Accountancy), CPA, has been Chief Executive Officer, Managing Director and Executive Director at Australian Pharmaceutical Industries Limited since February 15, 2017. Mr. Vi ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD856.05K) is about average for companies of similar size in the Australian market ($USD704.85K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
|MD, CEO & Executive Director||3yrs||AU$1.27m||0.098% A$609.5k|
|Chief Financial Officer||5.1yrs||AU$554.57k||0.0094% A$58.8k|
|Chief Information Officer||3.2yrs||no data||no data|
|General Counsel & Company Secretary||0.6yrs||no data||no data|
|General Manager of People||0yrs||AU$435.21k||no data|
|NSW State Manager||0yrs||AU$251.36k||no data|
Experienced Management: API's management team is considered experienced (3.1 years average tenure).
|MD, CEO & Executive Director||3yrs||AU$1.27m||0.098% A$609.5k|
|Non-Executive Director||19.8yrs||AU$110.99k||0.36% A$2.2m|
|Independent Non-Executive Director||5.8yrs||AU$178.07k||0.0061% A$38.0k|
|Non-Executive Chairman of the Board||2.1yrs||AU$243.06k||0.076% A$474.4k|
|Independent Non-Executive Director||11.3yrs||AU$110.99k||0.017% A$105.4k|
|Independent Non-Executive Director||2.3yrs||AU$110.99k||0.0071% A$44.2k|
Experienced Board: API's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: API insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Australian Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources
- Name: Australian Pharmaceutical Industries Limited
- Ticker: API
- Exchange: ASX
- Founded: 1910
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: AU$623.210m
- Shares outstanding: 492.66m
- Website: https://www.api.net.au
- Australian Pharmaceutical Industries Limited
- 250 Camberwell Road
- Level 5
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|API||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jun 1997|
|API||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jun 1997|
Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. The company also retails health and beauty products to consumers; and manufactures and distributes pharmaceutical and toiletry goods to New Zealand, Australian, and Asian markets, as well as provides cosmetic products and procedures. In addition, its services include wholesale product delivery, retail services, marketing programs, and business advisory services. The company markets its products and services under the Soul Pattinson Chemist, Pharmacist Advice, Club Premium, and Pharmacy Best Buys brand names, as well as through 488 Priceline and Priceline Pharmacy franchise stores, and company owned Priceline stores. Australian Pharmaceutical Industries Limited was founded in 1910 and is based in Camberwell, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 10:31|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.